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Summary: Some investigators argue that treating epi­
lepsy with several antiepileptic drugs (AEDs) simulta­
neously (polytherapy) may give rise to more adverse ef­
fects than monotherapy, but this argument lacks support­
ing quantitative data, To reexamine this issue, we 
recruited a cohort of patients from the outpatients of the 
Special Centres for Epilepsy in The Netherlands and from 
the outpatients of the Department of Neurology, Nij­
megen University, The Netherlands. Two tools were 
used for analysis. All daily doses of antiepileptic drugs 
(AEDs) were standardized by the ratio of prescribed daily 
dose to defined daily dose (PDD/DDD). The DDD is the 
assumed average effective daily dose for a drug used for 
its main indication in adults. The assignment of DDD val­
ues is the task of the World Health Organization (WHO) 
Collaborating Centre for Drugs Statistics Methodology 
and Nordic Council on Medicines, which regularly pub­
lishes Guidelines fo r  Defined Dally Doses.  The severity 
of adverse effects (AE) was assessed by using the Neu­
rotoxicity Index and the Systemic Toxicity Index as de­
veloped by the VA Cooperative Study Group for their 
recent studies comparing the efficacy and tolerability of 
AEDs. One hundred sixty-one patients received mono­
therapy; all had a PDD/DDD ratio ^2/day; 128 of 262 
patients receiving poly therapy also had ^2 PDD/DDD 
ratios/day. The mono- and poly therapy groups were strat-
ified according to the PDD/DDD ratio. The prevalence of 
neurological AE for patients with similar PDD/DDD ra­
tios was 50-80% for monotherapy patients and 50-82% 
for poly therapy patients. The difference between the 
mono- and polytherapy groups was not significant. The 
prevalence of neurological AE for patients receiving poly­
therapy with a PDD/DDD ratio >2.0  was 71-100%, 
whereas all patients with a PDD/DDD ratio >4.0 had neu­
rological AE. This difference between patients with a 
PDD/DDD ratio ^2.0 and those with >2.0 was statisti­
cally significant; p <  0.05. The severity of neurological 
AE also increased with dose, but appeared to peak at 
—3.5 PDD/DDD ratio. Our study underscores the useful­
ness of applying quantitative methods to the analysis of 
drug AE, Comparison of monotherapy and polytherapy 
showed no difference for equipotent doses. Because dis­
tribution of the AED doses was uneven between the 
groups receiving mono- and poly therapy, our study per­
mits only a tentative statement that the frequency and 
severity of AE is independent of the use of either. In 
addition, frequency and intensity of AE apparently are 
not very sensitive to changes in dose. An experimental 
prospective study is planned to verify or refute the con­
clusions of this observational pilot study. Key Words: Ep­
i lepsy— Antiepi lept ic  drugs— A d v e r s e  e f f e c t s — 
Monotherapy—Polytherapy— Clinimetrics.
Remaining seizure-free is sufficiently important 
for many patients with epilepsy for them to accept 
the adverse effects (AE) of continual use of antiep­
ileptic drugs (AEDs). The problem of toxicity of 
AEDs has been reviewed repeatedly (1-4). There is 
a long tradition of using several AEDs simulta­
neously for the treatment of epilepsy (polytherapy). 
Reynolds and Shorvon (5), however, signaled three 
major problems associated with this practice: (a)
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chronic toxicity, (b) exacerbation of seizures, and 
(c) drug interactions. The evidence lacks quantita­
tive support, however.
A few years ago, three special centers for epi­
lepsy in The Netherlands and the subdepartment of 
Epileptology of Nijmegen University decided to de­
termine whether further quantification of symptoms 
and signs could improve optimal management of ep­
ilepsy. Feinstein (6) has been a strong advocate of 
quantification. He recommends the use of the term 
clinimetric indices as the term for the rating scales 
that have been developed for clinical phenomena. 
To advance these studies of the feasibility and prof­
itability of using quantitative data, we examined
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whether the incidence and/or severity of AE was 
affected by the use of one AED (monotherapy) or 
several AEDs (polytherapy) to control seizures.
USE OF DEFINED DAILY DOSES (DDD)
We hypothesized that there should be no differ­
ence in either the frequency or the severity of AE if 
equipotent doses of AEDs are used. To compare 
the effect of one drug with the effect of a combina­
tion of several drugs a measure of equipotency must 
be determined. Therefore, all daily doses were stan­
dardized by using the ratio of prescribed daily dose 
to DDD (PDD/DDD). The PDD is the dose pre­
scribed by the physician for the individual patient 
and because only compliant patients were admitted 
to the study the PDD equals the actual daily dose. 
The DDD is the assumed average effective daily 
dose for the drug used for its main indication in 
adults and is expressed in amount of the active sub­
stance. DDD values are assigned by the World 
Health Organization (WHO) Collaborating Centre 
for Drugs Statistics Methodology and Nordic Coun­
cil on Medicines and are published in Guidelines for  
Defined D aily  D o ses , a publication based on dose 
documentations per drug as prepared by WHO- 
Oslo based on international textbooks, journals, 
and documentation approved by drug control au­
thorities. These dose documentations are available 
on request from Oslo (7). Table 1 shows the pub­
lished DDD of AEDs.
The rationale for summating PDD/DDD ratios of 
different AEDs is found in the definition of DDD as
TABLE 1. D D D  f o r  A E D s  as publ ished  by WHO 1991
AED DDD (mg)
Methylphenobarbital 500
Phénobarbital 100
Primidone 1,250
Metharbital 200
Ethotoin 2,500
Phenytoin 300
Amino (diphenylhydantoin) valeric acid 300
Mephenytoin 400
Paramethadione 900
Trimethadione 1,500
Ethosuximide 1,250
Phensuximide 2,000
Mesuximide 900
Clonazepam 8
Diazepam 10
Carbamazepine 1,000
Oxcarbazepine 1,000
Valproate 1,500
Aminobutyric acid 1,000
Vigabatrin 2,000
DDD, defined daily dose; AED, antiepileptic drug; WHO, 
World Health Organization.
the average maintenance dose of a particular drug 
for its main indication in adults. According to DDD 
methodology of the WHO, half of a DDD of AED-I 
plus half of a DDD of AED-II should be as effective 
as a full dose of either, e.g., 750 mg valproate (VP A) 
plus 500 mg carbamazepine (CBZ) should be as ef­
fective as 1,500 mg VPA or 1,000 mg CBZ.
Because we were interested only in comparing 
AE in monotherapy and poly therapy, efficacy of 
monotherapy and polytherapy was not assessed in 
this study. Efficacy would be related to the severity 
of the epilepsy. There is no a priori reason to expect 
that sensitivity to toxic effects of AEDs is related to 
the severity of the epilepsy.
QUANTIFICATION OF AE
Studies of AEDs rarely use quantitative data to 
describe the clinical AE. Quantitative data have 
been largely restricted to laboratory findings or the 
results of psychological tests, both of which are in­
trinsically quantified. When semiquantification is 
used, categories are usually poorly defined and 
terms such as mild, moderate, or severe are used, 
with no explanation of their precise meaning (8). 
Recently, however, the use of a clinimetric ap­
proach to epilepsy management has been increas­
ing. In previous studies of clinimetrics and epilepsy 
care (9-12), we noted that the rating scales devel-
s  «
oped by the VA Cooperative Study Group are a 
suitable tool for this purpose (13,14).
MATERIALS AND METHODS 
Population
The Netherlands is exceptional in that it has a 
long tradition of tertiary care. Three special centers 
provide both intramural and extramural tertiary 
care nationwide for persons with difficult-to-treat 
epilepsies. The country has a national network of 16 
outpatient clinics associated with these centers (ap­
proximately one clinic for each 1 million inhabit­
ants). Patients attending these clinics are always ex­
amined by the same physician, and there is a high 
level of compliance.
For the present study, the data on medication and 
AE recorded at the first assessment of the patients 
recruited in the years 1991 through 1993 for previ­
ous studies of the use of quantitative data (10-12) 
were collected in to to. All patients were either at­
tending an outpatient clinic of one of the special 
centres for epilepsy or of a university hospital neu­
rology department. The study was approved by the 
ethical committees of the participating institutes: 
Patients aged ^15 years whose seizures could be 
defined accurately according to the International
Epilepsia, Vol. 36, No. 5, 1995
442 M. W. LAMMERS ET AL.
Classification of the International League Against 
Epilepsy (ILAE) were included in the study. Pa­
tients with factors that were believed to complicate 
the evaluation of whether a clinimetric approach
»
has added value over present patient management 
were excluded from the study; these factors in­
cluded progressive brain disorders, obvious non- 
compliance in drug usage or seizure registration, 
pseudoseizures, and severe mental retardation.
Indexes
The Indexes used in this study were first de­
scribed by Cramer et al. (13) for use in the evalua­
tion of AED therapy. Subsequently, Wijsman et al. 
(9) made minor adaptations to enable their routine 
use in epilepsy management. These indexes con­
sisted of the Index of Seizures (IS) measuring the 
seizure frequency modulated by seizure type. The 
Seizure Activity Index (SA), which is a further 
modulation takes into account the possible pres­
ence of an aura, seizure-provoking factors, cluster­
ing of seizures, occurrence of seizures only during 
sleep or at awakening, and the interval for complete 
recovery after the seizure. The Neurotoxicity Index 
(NTX) rates the presence and severity of common 
neurological symptoms commonly considered AE 
associated with AED use. The Systemic Toxicity 
Index (STX) rates the presence and severity of dis­
turbances in different organs, some due to idiosyn­
cratic reactions. The scores per symptom range 
from 0 to 50 (Table 2). The Composite Index of 
Impairments (CII) is the sum of the SA and toxicity 
ratings.
TABLE 2. R ange o f  toxicity scores  p e r  sym p to m  as  
u se d  in the C om posite  Index o f  Im pairm ents
Toxicity Scoring range
Neurotoxicity
Diplopia 15-30
Nystagmus 5-10
Dysarthria 5-30
Ataxia 5-50
Dysdiadochokinesis 15
Tremor 10-50
Sedation 5-50
Affect and mood disturbances 5-50
Cognitive impairments 5-50
Dizziness 3-50
Headache 3-50
Systemic toxicity
Gastrointestinal problems 3-50
Haematopoietic problems 50
Dermatologie problems 20-50
Impotence 20-50
Kidney disease 50
Liver disease 25-50
Weight gain 3-20
Changes in hair/hair loss 5-50
Patient data collection
Before the start of the study, patients meeting the 
inclusion criteria were informed about the purpose 
and the procedure of the study and asked to collab­
orate. None refused. On the day of their regular 
visit the patients were interviewed and examined 
for —30 min by the investigator to obtain data nec­
essary to determine the value of the indexes. Data 
from all patients receiving monotherapy (n = 161) 
and also from patients receiving polytherapy with a 
PDD/DDD ratio in the same range (n = 128) were 
examined. Therefore, 289 patients entered the main 
arm of the study; the maximum PDD/DDD ratio 
was 2.0. All patients with a PDD/DDD ratio >2.0 (n 
= 134) were in the poly therapy group. The poly­
therapy group as a whole (n = 262) was also studied 
separately in comparisons of patients receiving 
poly therapy with a PDD/DDD ratio of ^2.0 and 
>2.0. The patients were stratified according to the 
PDD/DDD ratio with intervals of 0.33 PDD/DDD 
ratio and the prevalence and severity (NTX, STX) 
of AE was studied in each stratum (Tables 3 and 4). 
Although serum levels of AEDs were available, 
they were not included in this study because AE 
might be due to metabolites, the entire spectrum of 
which was not measurable.
Statistical analysis
Because of the size of the strata, Fisher’s exact 
test (two-tailed) was applied for the assessment of 
differences in gender, for the study of the overall 
prevalence of AE, and for the prevalence per stra­
tum of PDD/DDD ratios. The Kruskal-Wallis test 
was used for the assessment of differences in the 
severity of AE. Differences were considered statis­
tically significant at p <  0.05. Multiple-regression 
analysis was used to investigate whether gender, 
age, duration of epilepsy, or the use of either mono- 
or polytherapy in themselves or combined could ex­
plain the variance in outcome of the toxicity scores. 
However, no factor reached significance.
RESULTS
Population
Of 289 patients entering the main study, 124 were 
men (43%) and 165 were women (57%). No statis­
tically significant difference was noted in the gender 
distribution between patients receiving monother­
apy and those receiving polytherapy with a PDD/ 
DDD ratio ^2.0.
The mean age of the patients receiving monother­
apy was 37 years (range 15-76 years); that of pa­
tients receiving poly therapy was 43 years (range 15- 
75 years). This difference in mean ages between
Epilepsia, Vol. 36, No. 5, 1995
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TABLE 3. Prevalence and severity o f neurological AE per dose for patients receiving
monotherapy and poly therapy
Monotherapy NCS Polytherapy NCS
PDD/DDD ratio n % Median score (25-75%) n % Median score (25-75%)
0.01-0.33 10 50 5 (5-5)
0.34-0.66 62 60 10 (5-15) 2 50 35 (35-35)
0.67-1.00 64 72 10 (8- 20) 16 75 9 (5-15)
1.01-1.33 18 78 10 (5-20) 17 82 16 (5-28)
1.34-1.66 4 75 15 (10-30) 45 63 15 (10-25)
1.67-2.00 3 67 17 (5-30) 48 81 15 (13-25)
AE, adverse effects; NCS, neurotoxicity cumulative score; n, number of patients per stratum; %, 
percentage of patients with AE per stratum.
patients treated with monotherapy and polytherapy 
was statistically significant (p = 0.0001).
A statistically significant difference was also 
noted for the mean duration of epilepsy between 
patients receiving monotherapy (18 years, range 1- 
64 years) and those receiving poly therapy (26 years,
range 1-70 years) (p 0.0001). For the patients
receiving polytherapy with a PDD/DDD ratio >2.0, 
the mean age was 44 years (range 15-80 years) and 
the duration of epilepsy was 27.5 years (range 2-70 
years). No statistical difference was noted in age 
and duration of epilepsy between this group and the 
group of patients receiving polytherapy with a PDD/ 
DDD ratio ^2.0.
Number of AEDs prescribed in polytherapy 
The distribution of the number of AEDs over the 
various PDD/DDD ratios for all patients is shown in 
Table 5. Sufficient numbers were available in only 
two classes to allow comparison of the neurotoxic 
and systemic toxic effects according to the number 
of drugs used in polytherapy. Respectively, 38 pa­
tients with a PDD/DDD ratio of 1.67-2.00 used two 
drugs and 10 patients used three drugs, whereas 11 
patients with a PDD/DDD ratio of 2.34-2.66 used 
two drugs and 14 patients used three drugs.
AE prevalence and severity 
Overall, no significant differences in’the preva­
lence of AE was noted between patients receiving 
monotherapy and polytherapy who had similar
PDD/DDD ratios (Tables 3 and 4). Separate deter­
minations of neurotoxicity and systemic toxicity did 
not change that finding. When specific AE were 
considered, the only significant differences in prev­
alence were sedation (37% in those receiving mono­
therapy and 52% in those receiving polytherapy, p 
< 0.05) and cognitive impairment (27% in those re­
ceiving monotherapy and 34% in those receiving 
polytherapy, p <  0.05) (Table 6). In both groups, 
sedation was the most common AE. The prevalence 
of individual systemic AE did not differ between the 
groups.
Neither the cumulated scores nor the median 
scores for intensity of each specific AE differed sig­
nificantly between patients treated with monother­
apy and those treated with poly therapy. Neither did 
the distribution of the severity scores for the AE 
separately differ between patients treated with 
monotherapy and those treated with poly therapy.
AE prevalence and severity for PDD/DDD 
ratio >2.0
The prevalence of AE in patients receiving poly­
therapy with a PDD/DDD ratio >2.0 was greater 
than that in patients receiving polytherapy with a 
PDD/DDD ratio =^ 2.0: 91 and 78%, respectively. 
This difference was statistically significant (p <  
0.05), The prevalence of neurological AE effects 
showed some increase with higher doses of AEDs, 
although this finding was not statistically signifi-
TABLE 4. Prevalence and severity o f systemic AE per dose for patients on
monotherapy and polytherapy
Monotherapy SCS Poly therapy SCS
PDD/DDD ratio n % Median score (25-75%) n % Median score (25-75%)
0.01-0,33 10 10 3 (3-3) < ----------------- _
0.34—0.66 62 23 10 (5-15) 2 --------------------
0.67-1,00 64 22 6 (3-15) 16 31 10 (10- 20)
1.01-1.33 18 33 5 (5-15) 17 24 25 (16-27)
1.34-1.66 4 25 50 (50-50) 45 23 10 (8-15)
1.67-2.00 3 33 10 (10- 10) 48 29 12 (5-25)
SCS, systemic toxicity cumulative score; other abbreviations as in Table 3.
Epilepsia, Vol. 36, No. 5, 1995
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TABLE 5. Distribution o f  the num ber o f  A E D s over  the
various P D D ID D D  ratios
AEDs
PDD/DDD ratio 1 4
0.01-0.33 10 -- 1
0.34-0.66 62 1 --
0.67-1.00 64 16 ---
1.01-1.33 18 17 --
1.34-1.66 4 42 3
1.67-2.00 3 38 10
2.01-2.33 .-- 23 5
2.34-2.66 -- 11 14
2.67-3.00 --- 9 14
3.01-3,33 — 1 13
3.34-3.66 --- — 8
3.67-4.00 --- --- 7
4.01-4.33 -- -- 6
4.34—4.66 --- -- - 1
4.67-5.00 ■-- --- 1
5.01-5.33 -- -- 2
5.34-5.66 -- 1
5
2
3
4 
1 
2
1
PDD, prescribed daily dose; other abbreviations as in Table 1.
cant. The severity of neurological AE also in­
creased with higher doses, but appeared to peak at 
a PDD/DDD ratio level of 3.67-4.00 (Table 7).
AE and number of AEDs 
No statistically significant difference was noted 
between the patients receiving two AEDs and three 
AEDs with respect to the prevalence and severity 
of neurological AE. Systemic AE occurred more 
frequently in the patients using three AEDs, al­
though the severity did not differ.
DISCUSSION
Prevalence of polytherapy
Reynolds and Shorvon (5) remarked that “There 
seems little doubt that polytherapy has character­
ized the treatment of epilepsy throughout the
Textbooks over the years contain littleages.
evidence that the use of poly therapy has been based 
solely on rational choice. Guelen et al. (15) col­
lected data on plasma concentrations of AEDs from
11 institutions in The Netherlands, Norway, En­
gland, Germany, and the U.S., obtaining informa­
tion on 11,720 patients from 1969 to 1974. The av­
erage number of AEDs prescribed per patient in 
that period was 3.2, of which 85% consisted of 
AEDs and 15% of stimulants such as amphetamines 
or caffeine, and/or vitamins and/or neuroleptic 
drugs. Only 4.2% were treated with single drug. 
Thanks to the advocacy of Reynolds and Shorvon 
(5) and other epileptologists, most physicians who 
now treat epilepsy initiate treatment with a single 
AED. In a previous study, we examined 225 pa­
tients from the special centers for epilepsy and
noted an average use of 2.0 AED per patient, but 
only 28% were receiving monotherapy (10). Those 
treated with polytherapy received an average of 2.4 
AEDs per patient. One hundred twenty patients 
from the University Hospital Nijmegen received an 
average of 1.4 AED/patient and 62.5% were treated 
with monotherapy. Those treated with polytherapy 
received an average of 2,1 AEDs per patient. Poly­
therapy is therefore still an issue. In the present 
study we examined pooled data from the epilepsy 
centers and Nijmegen University. Of the 423 pa­
tients, 38% received monotherapy. Those treated 
with polytherapy received 2.45 AEDs on the aver­
age.
Possible confounders
The data from our patients have been standard­
ized in two respects. AE of AEDs were assessed 
quantitatively with respect to both the prevalence 
of the AE and their severity. The scores are pre­
sumed to be independent of the type of the drug 
responsible. The AED doses were standardized by 
the PDD/DDD ratio. The concept of adding frac­
tions of the DDD as a measure of drug exposure 
obviously does not take into account linearity of 
dose-effect relationships of metabolic or dynamic 
interactions of the drugs in individuals, but the con­
cept has been used extensively in pharmacoepide- 
miological studies (16).
Because our study is a prospective observational 
study, it has an inherent weakness: The parameters 
could not be set according to the demands of the 
study. All patients visiting the outpatient clinic who 
met the entry criteria were studied. The patients 
receiving monotherapy and those receiving poly­
therapy did not differ with respect to gender but 
differed significantly with respect to mean age and 
mean duration of epilepsy. Patients receiving mono­
therapy were on the average, younger and had had 
epilepsy for a shorter time. Whether this difference 
influences the occurrence of AE cannot be judged 
from our study. When the results were assessed by 
multiple-regression analysis, age and duration did 
not explain the variance in frequency and severity 
of AE. The patients treated with poly therapy with a 
PDD/DDD ratio ^2.0 and those with a PDD/DDD 
ratio >2.0 did not differ significantly either in gen­
der, age, or duration of epilepsy.
In the main arm of the study (n = 289), 71% of 
patients receiving monotherapy and 79% receiving 
poly therapy had AE. This result from a prospective 
study contrasts with the results obtained in a retro­
spective study (9): 20.9% of patients receiving 
monotherapy and 20.5% receiving polytherapy had 
AE. Our results are more in agreement with those
Epilepsia, Voi, 36, No. 5, 1995
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TABLE 6. Distribution o f  AE in monotherapy and poly therapy
Effects
Monotherapy (n = 161) Poly therapy (n = 128)
% Median score (25-75%) % Median score (25-75%)
Neurological
Diplopia 5,0 15 (15-15) 10.2 15 (15-15)
Nystagmus 6.2 5 (5-10) 9.4 5 (5-5)
Dysarthria 6.8 5 (5-5) 6.3 5 (5-7.5)
Ataxia 11.8 5 (5-15) 14.8 5 (5-15)
Dysdiadochokinesis 1.2 15 (15-15) 1.6 10 (5-15)
Tremor 18.0 10 (10- 10) 22.7 10 (10- 10)
Sedation 37.3 5 (5-5) 52.3 5 (5-10)
Affect and mood disturbances 6.2 5 (5-5) 10.9 5 (5-5)
Cognitive impairments 26.7 5 (5-5) 34.4 10 (5-10)
Dizziness 7.5 5 (3-7.5) 10.9 5 (3-5)
Headache 9.3 5 (5-10) 10,2 5 (3-10)
Systemic
Gastrointestinal problems 5.0 4 (3-7.5) 9.4 4 (3-10)
Hematopoietic problems ------------------- —
Dermatological problems 1.9 15 (15-15) 3.9 15 (15-15)
Impotence 0.6 50 (50-50) 1.6 25 (25-25)
Kidney disease ------------------- —
Liver disease ------------------- -------------------
Weight gain 11.2 10 (3-10) 8.6 10 (3-20)
Change in hair/hair loss 12,4 5 (5-5) 15.6 5 (5-7.5)
n, number of patients per therapy group; %, percentage of patients with adverse effects [(AE); some 
had multiple AE].
of the prospective study of Keyser et al (17), in 
which 57.3% of the patients reported AE and that of 
the Collaborative Group of Epidemiology of Epi­
lepsy (18) of Milan, Italy, in which 41.6% of the 
patients had AE. The selection of patients for these 
two studies does not allow detailed comparison, 
Comparison of patients receiving monotherapy 
and those receiving polytherapy with similar PDD/ 
DDD ratios showed no overall difference in either 
prevalence or severity of neurological and systemic 
AE. It is remarkable that on stratification neither 
the frequency nor the severity increased notably 
per stratum, although they tended toward increase. 
Because ours was an observational study, our re­
sults may well reflect the practice not to increase 
dose beyond a tolerable level. The dose tolerated 
may differ from person to person, however. Anal­
ysis of the data of patients receiving polytherapy 
showed an increase in frequency of AE to 100% 
when the PDD/DDD ratio increased to >3.0. The 
severity of AE increased at a PDD/DDD ratio of 
3.67-4.00, followed by a decrease at higher doses. 
We attribute this to the practice of administering 
such high doses only to patients who are relatively 
insensitive to AE. Patients receiving poly therapy 
had a significantly longer duration of epilepsy, 
which may have led to the development of tolerance 
to some AE, and thus to a lower prevalence and
TABLE 7. Prevalence and severity o f  neurological and systemic A E for PDDIDDD
ratio >2 .0
PDD/DDD ratio
Polytherapy (n = 134) Polytherapy (n 11
1
NTX STX
n % Median NCS n % Median SCS
2.01-2.33 28 71 20.0 28 32 10.0
2.34-2.66 30 83 15.0 30 23 20.0
2.67-3.00 23 83 19.0 23 35 15.0
3.01-3.33 14 93 20.0 14 50 20.0
3.34-3.66 10 100 21.5 10 40 12.5
3.67-4.00 10 90 35.0 10 30 3.0
4.01-4.33 10 100 25.5 10 10 3.0
4.34-4.66 2 100 25.0 2 50 25.0
4.67-5.00 3 100 15,0 3 ------------------- --------------------
5.01-5.33 2 100 10.0 2 100 25.0
5.34-5.66 2 100 13.0 2 — --------------------
Abbreviations as in Tables 1,3, and 4.
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severity. This possibility could not be confirmed in 
the context of this study and will require further 
investigation.
Lack of correlation
The prevalence of AE in the group receiving 
polytherapy (n = 262) was greater for patients with 
a PDD/DDD ratio of >2.0. No correlation was 
noted between the number of AEDs and prevalence 
of neurological AE which again suggests that the 
occurrence and the severity of AE are influenced by 
the total dose and not by the number of AEDs pre­
scribed. Keyser et al. (17) showed that patients 
treated with polytherapy had a higher prevalence of 
AE than did patients treated with monotherapy. In 
that study, all patients were compared, irrespective 
of the dose of medication, in contrast to the patients 
in the main arm of the present study in which only 
patients with similar PDD/DDD ratios were com­
pared.
Sedation and cognitive impairment were the two 
more frequent neurological AE in patients receiving 
polytherapy. However, there was no difference in 
the intensity (median level of NTX score) of these 
AE between the two groups. There is no primafacie 
explanation for this finding, which obviously re­
quires further study.
Our results underscore the feasibility of applying 
clinimetric methods to the analysis of AE of drugs. 
Frequency and intensity of AE apparently are not 
very sensitive to changes in dose. Neither was any 
difference noted between monotherapy and poly­
therapy. Because the distribution of the dose of 
AEDs was uneven between the groups receiving 
mono- and polytherapy, our study permits only a 
tentative conclusion that the frequency and severity 
of AE is independent of the use of either. Longer 
duration of epilepsy in the cohort on polytherapy, 
might be supposed a complicating factor but this 
possibility was not confirmed by the statistical anal­
ysis. An experimental study is planned to verify or 
refute the conclusions of this observational study,
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